| FLOX | FLOX + cetuximab |  | ||||
---|---|---|---|---|---|---|---|
 | F/F | F/V | V/V | F/F | F/V | V/V | Interaction P-value |
KRAS wild-type (N =268) | |||||||
Number of patients | N = 39 | N = 38 | N = 9 | N = 87 | N = 73 | N = 22 | Â |
Response | 44% (17/39) | 45% (17/38) | 56% (5/9) | 48% (42/87) | 51% (37/73) | 55% (12/22) | 0.95* |
PFS | 7.8 | 9.0 | 8.4 | 8.0 | 7.3 | 11.8 | 0.72†|
OS | 23.1 | 20.5 | 25.2 | 17.6 | 25.9 | 20.5 | 0.97†|
KRAS mutated (N =169) | |||||||
Number of patients | N = 28 | N = 21 | N = 6 | N = 59 | N = 46 | N = 9 | Â |
Response | 36% (10/28) | 48% (10/21) | 50% (3/6) | 51% (30/59) | 39% (18/46) | 33% (3/9) | 0.28* |
PFS | 7.8 | 8.1 | 4.0 | 8.3 | 7.0 | 6.9 | 0.19†|
OS | 18.5 | 24.3 | 17.1 | 21.3 | 17.7 | 16.4 | 0.63†|
BRAF wild-type (N = 359) | |||||||
Number of patients | N = 56 | N = 47 | N = 12 | N = 126 | N = 94 | N = 24 | Â |
Response | 45% (25/56) | 49% (23/47) | 50% (6/12) | 52% (65/126) | 48% (45/94) | 63% (15/24) | 0.71* |
PFS | 7.9 | 9.1 | 7.8 | 8.3 | 7.6 | 11.5 | 0.58†|
OS | 23.8 | 23.6 | 19.7 | 20.6 | 22.9 | 20.5 | 0.93†|
BRAF mutated (N = 46) | |||||||
Number of patients | N = 8 | N = 7 | N = 2 | N = 10 | N = 14 | N = 5 | Â |
Response | 13% (1/8) | 14% (1/7) | 50% (1/2) | 20% (2/10) | 29% (4/14) | 0% (0/5) | 0.99* |
PFS | 5.9 | 4.3 | 4.4 | 4.2 | 5.4 | 4.6 | 0.87†|
OS | 9.5 | 9.4 | 5.2 | 10.8 | 8.9 | 10.3 | 0.66†|